Core Viewpoint - The hair medical concept sector has shown a positive performance with a 1.77% increase, ranking 7th among various concept sectors, driven by significant gains in stocks like Xiaofang Pharmaceutical, Baicheng Pharmaceutical, and Jiuzhitang [1] Group 1: Sector Performance - The hair medical concept sector experienced a 1.77% increase, with 17 stocks rising, including Xiaofang Pharmaceutical (up 6.65%), Baicheng Pharmaceutical (up 6.05%), and Jiuzhitang (up 6.00%) [1] - The sector attracted a net inflow of 114 million yuan from main funds, with Jiuzhitang leading the inflow at 74.56 million yuan [1] Group 2: Fund Inflow Ratios - Baicheng Pharmaceutical, Aoyang Health, and Yisheng Pharmaceutical had the highest net inflow ratios at 10.73%, 7.21%, and 6.37% respectively [2] - Jiuzhitang recorded a net inflow of 74.56 million yuan with a turnover rate of 27.18% [2] - Other notable stocks include Langzi Co. (up 5.16% with a net inflow of 20.14 million yuan) and Aoyang Health (up 1.03% with a net inflow of 10.81 million yuan) [2]

Core Viewpoint - The innovative drug sector experienced a rebound, with CXO direction leading the gains, as several companies saw significant stock price increases, indicating growing confidence in China's innovative drug capabilities on the international stage [1] Group 1: Market Performance - Companies such as Puris, Medici, Jiuzhitang, Sali Medical, Huanyu Pharmaceutical, and Shanghai Yizhong all reported stock price increases, with Puris rising over 10% and others exceeding 6% [1] Group 2: Industry Insights - CICC released a report highlighting that the recent disclosures of numerous clinical data at ASCO, along with significant business development (BD) deals represented by Sanofi, further confirm the international competitiveness of Chinese innovative drugs [1] - The upcoming ESMO conference and the data disclosures surrounding it are expected to positively catalyze the innovative drug sector [1]

Market Performance - The hair medical concept sector rose by 2.34%, ranking 10th among concept sectors, with 19 stocks increasing in value, including JiuZhiTang which hit the daily limit, and TianEnKang, KangHui Pharmaceutical, and KangYuan Pharmaceutical which rose by 6.42%, 5.16%, and 4.55% respectively [1] - The top gainers in today's market include the fruit index at 4.73%, PCB concept at 3.27%, and AI mobile at 2.92%, while the military restructuring concept saw a decline of 1.49% [1] Capital Flow - The hair medical concept sector experienced a net inflow of 219 million yuan, with 11 stocks receiving net inflows, and 5 stocks seeing inflows exceeding 10 million yuan. JiuZhiTang led with a net inflow of 172 million yuan, followed by ShuiYang Co., KangYuan Pharmaceutical, and NengTe Technology with net inflows of 34.25 million yuan, 21.05 million yuan, and 13.44 million yuan respectively [1] - In terms of capital inflow ratios, JiuZhiTang, ShuiYang Co., and KangHui Pharmaceutical had the highest net inflow rates at 33.17%, 6.81%, and 6.15% respectively [2] Stock Performance - JiuZhiTang saw a significant increase of 10.06% with a turnover rate of 7.62%, while ShuiYang Co. and KangYuan Pharmaceutical increased by 3.12% and 4.55% respectively [2] - Stocks such as *ST JinBi and AoYang Health experienced declines of 0.69% and 0.26% respectively, indicating some volatility within the sector [1][3]

Group 1 - The innovative drug concept sector rose by 2.49%, ranking 7th among concept sectors, with 196 stocks increasing in value [1] - Notable gainers included Guoshentang and Shenzhou Cell, both reaching a 20% limit up, while stocks like Jiuzhitang, Weiming Pharmaceutical, and Huahai Pharmaceutical also hit the limit up [1] - The top gainers in the sector included Shanghai Yizhong, Saiseng Pharmaceutical, and Rejing Biomedical, with increases of 10.82%, 10.45%, and 10.38% respectively [1] Group 2 - The innovative drug sector saw a net inflow of 1.887 billion yuan, with 122 stocks receiving net inflows, and 6 stocks exceeding 100 million yuan in net inflow [2] - Huahai Pharmaceutical led the net inflow with 269 million yuan, followed by Changchun Gaoxin, Zhongsheng Pharmaceutical, and Jiuzhitang with net inflows of 266 million yuan, 178 million yuan, and 172 million yuan respectively [2] - The stocks with the highest net inflow ratios included Jiuzhitang, Weiming Pharmaceutical, and Huahai Pharmaceutical, with net inflow ratios of 33.17%, 24.18%, and 17.37% respectively [3] Group 3 - The innovative drug sector's top stocks by trading volume included Huahai Pharmaceutical, Changchun Gaoxin, and Zhongsheng Pharmaceutical, with trading volumes of 26.863 million yuan, 26.640 million yuan, and 17.787 million yuan respectively [3][4] - Other notable stocks included Guoshentang, which had a trading volume of 13.697 million yuan, and Weiming Pharmaceutical with 8.946 million yuan [4] - The sector's performance was characterized by significant trading activity, with many stocks experiencing high turnover rates [4]

Group 1 - The ChiNext index showed strong performance, rising over 1% with active participation from innovative drug and commercial aerospace concepts [1][2][3] - The ChiNext index rose by 1.36% at midday, with notable stocks such as Lens Technology (300433) increasing over 8% and Ningde Times (300750) nearly 4% [2][3] - The innovative drug concept saw significant gains, with multiple stocks hitting the daily limit, including ShenZhou Cell and Jiuzhitang [3][6] Group 2 - The Hong Kong stock market experienced a slight decline, with the Hang Seng Index dropping over 1% at one point [9] - Multi-point Intelligence saw its stock price surge, with an intraday increase nearing 90%, attributed to its plans for a stablecoin license [10][12] - The pharmaceutical sector in the Hong Kong market rose over 2%, with several stocks, including Huahao Zhongtian Pharmaceutical-B, increasing over 10% [12] Group 3 - JiXin Technology (601218) experienced its fourth consecutive trading day of hitting the daily limit, while issuing a risk warning regarding its high rolling P/E ratio of 72.85 compared to the industry average of 22.24 [7][8] - SaiLi Medical also hit the daily limit for the third consecutive day, with the company confirming no undisclosed significant information affecting its stock price [8]

Core Insights - The demand for grape seed health products is increasing due to rising living standards and health awareness among consumers [1][16] - The market size of grape seed health products in China is projected to grow from 5 billion yuan in 2019 to 9 billion yuan by 2024, with a compound annual growth rate of 12% [1][16] - Technological advancements in extraction efficiency and purity are supporting the growth of the grape seed health product market [1][16] Industry Overview - Grape seed health products are derived from grape seeds and contain beneficial components such as vitamins, minerals, amino acids, and antioxidants, offering various health benefits [3][10] - The industry can be categorized by product form (tablets, capsules, liquid), efficacy (antioxidant, anti-aging), and usage scenarios (daily health, beauty, sports nutrition) [5][10] Market Dynamics - The grape seed health product market is experiencing rapid expansion due to the growth of e-commerce and diversified marketing channels [1][16] - The increase in grape production in China, from 13.16 million tons in 2015 to 16.17 million tons in 2023, is expected to provide ample raw materials for grape seed health products [12][14] Regulatory Environment - Recent policies in China aim to promote the integration of the food industry with health and wellness sectors, enhancing the market for functional foods and health products [6][9] Competitive Landscape - Major players in the grape seed health product market include well-known domestic brands such as汤臣倍健 (Tongrentang), 康恩贝 (Kang En Bei), and 九芝堂 (Jiu Zhi Tang), as well as international brands like Nature's Way and NOW Foods [18][19] - Companies are enhancing their competitiveness through improved production technologies and brand marketing strategies [18][19] Consumer Trends - There is a notable increase in consumer demand for high-quality grape seed health products, particularly among women and young adults aged 18 to 35, who represent 83.7% of the health supplement market [24][25] - Consumers are increasingly focused on product quality, efficacy, and safety, necessitating continuous improvement in product formulations [24][25] Future Outlook - The industry is expected to benefit from technological advancements that enhance product absorption and bioavailability [25][26] - The trend of online and offline integration in sales channels is becoming crucial for market growth, providing consumers with a more convenient shopping experience [26][27] - International expansion is a growing trend, with Chinese companies leveraging their resources and technology to compete in global markets [27]

Group 1 - The core point of the announcement is the decision made during the 7th meeting of the 9th Board of Directors of Juzhitang Co., Ltd., which includes the nomination of three non-independent director candidates and the scheduling of the first extraordinary general meeting of shareholders in 2025 [3][6][10]. Group 2 - The 7th meeting of the 9th Board of Directors was held on June 26, 2025, with all 7 directors present, and it complied with relevant laws and regulations [2][7]. - The board approved the nomination of Wang Lifeng, Wu Qiang, and Yu Zhongfei as candidates for non-independent directors, with unanimous support from all present directors [3][4][5]. - The first extraordinary general meeting of shareholders is scheduled for July 17, 2025, to discuss the aforementioned nominations [6][19]. Group 3 - The resignations of Chairman Sun Guangyuan and directors Lu Ming and Bo Jinfeng were reported, effective immediately upon delivery of their resignation letters [10][11]. - The board expressed gratitude for the contributions made by the resigning directors during their tenure [11]. - The company will proceed with the election of new directors to fill the vacancies created by these resignations [11]. Group 4 - The extraordinary general meeting will adopt a cumulative voting system for the election of the three non-independent directors, allowing shareholders to allocate their votes among the candidates [26][30]. - The meeting will be held both in-person and via online voting, with specific time slots designated for each [22][23]. - The registration for the meeting will take place on July 14, 2025, and shareholders must provide necessary documentation to participate [27][28].

Group 1 - The board of directors of JiuZhiTang Co., Ltd. held its seventh meeting of the ninth session on June 26, 2025, with all seven directors present [1][2] - The board approved the nomination of Wang Lifeng, Wu Qiang, and Yu Zhongfei as non-independent director candidates, with unanimous support of 7 votes for each nomination [1][2] - The first extraordinary general meeting of shareholders for 2025 is scheduled for July 17, 2025, to review the nominations [2]

公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2025-052 九芝堂股份有限公司 关于部分董事辞职暨补选董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 本公司董事会于近日收到董事长孙光远、董事吕鸣、董事薄金锋的辞职报告。 因工作变动原因，孙光远辞去公司第九届董事会董事长、董事、法定代表人及在 董事会下属专门委员会所兼任的其他职务，吕鸣、薄金锋辞去公司第九届董事会 董事及在董事会下属专门委员会所兼任的其他职务，孙光远、吕鸣、薄金锋辞职 后将不再担任公司及公司控股子公司任何职务。截至本公告披露日，孙光远、吕 鸣、薄金锋未持有公司股份，不存在应履行而未履行的承诺事项。 根据《公司法》和《公司章程》的有关规定，孙光远、吕鸣、薄金锋辞职不 会导致公司董事会成员低于法定人数，其辞职报告自送达董事会之日起生效。为 保障公司的日常经营不受影响，公司董事会征得孙光远本人同意，在公司按照法 定程序选举产生新任董事长之前，其将继续履行公司董事长及法定代表人职责。 公司将尽快按照法定程序完成补选董事及选举董事长工作。孙光远、吕鸣、薄金 锋在任职期间恪尽职 ...

公告文件 一、召开会议基本情况 1、股东大会届次：2025 年第一次临时股东大会 2、会议召集人：九芝堂股份有限公司董事会 证券代码：000989 证券简称：九芝堂 公告编号：2025-051 九芝堂股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 （2）网络投票时间： 通过深圳证券交易所（以下简称"深交所"）交易系统进行网络投票的具体时 间为 2025 年 7 月 17 日上午 9:15—9:25，9:30—11:30，下午 13:00—15:00； 通过深交所互联网投票系统投票的具体时间为：2025 年 7 月 17 日上午 9:15 至下午 15:00 的任意时间。 5、会议召开方式：本次股东大会采用现场表决与网络投票相结合的方式召开。 6、会议的股权登记日：2025 年 7 月 10 日 3、会议召开的合法、合规性： 本次股东大会召集、召开的程序符合有关法律、行政法规、部门规章、规范 性文件和公司章程的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025 年 7 月 17 日（ ...